Search Results
Your search for ,foR matches 32797 pages
Showing 8751 - 8800Disease Risk Associated With Protein-Truncating and Rare Missense Variants in Breast Cancer Risk Genes
In a study reported in TheNew England Journal of Medicine, Leila Dorling, PhD, of the Centre for Cancer Genetic Epidemiology, Departments of Public Health and Primary Care, University of Cambridge, United Kingdom, and colleagues in the international Breast Cancer Association Consortium (BCAC),...
New Medical Director Named to Lead Clinical Cancer Research
The University of California (UC) Davis Comprehensive Cancer Center has named Edward Kim, MD, PhD, as Medical Director for the Office of Clinical Research. Dr. Kim is a UC Davis Health oncologist and Associate Professor of Internal Medicine who specializes in treating gastrointestinal...
The Wistar Institute Recruits Noam Auslander, PhD, as Assistant Professor
The Wistar Institute, an international biomedical research leader in cancer, immunology, and infectious diseases, recently announced the appointment of Noam Auslander, PhD, as Assistant Professor in the Molecular and Cellular Oncogenesis Program of The Wistar Institute Cancer Center. Dr....
Caryn Lerman, PhD, Elected President of the AACI
Caryn Lerman, PhD, is the new President of the Association of American Cancer Institutes (AACI). Dr. Lerman is Director of the University of Southern California (USC) Norris Comprehensive Cancer Center in Los Angeles and Associate Dean for Cancer Programs and the H. Leslie and Elaine S. Hoffman...
Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
On May 20, 2021, nivolumab was approved for adjuvant treatment of patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease after neoadjuvant chemoradiotherapy.1,2 Supporting Efficacy Data Approval was based on findings from the...
5- vs 2-Year Course of Zoledronate for Patients With Early Breast Cancer
On this week's episode, we’re discussing the effect of a 5- vs 2-year course of zoledronate for patients with early breast cancer; a recent FDA approval in locally advanced cutaneous squamous cell carcinoma; and a study that examined how reduced time to completion of treatment in patients with...
Enfortumab Vedotin-ejfv Granted Regular Approval in Treatment of Locally Advanced or Metastatic Urothelial Cancer
On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev), a Nectin-4–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and...
Study Finds Response to COVID-19 Vaccination Varies Widely in Patients With Multiple Myeloma
Patients with multiple myeloma had a wide variety of responses to COVID-19 vaccines—in some cases, no detectable response at all—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published by Van Oekelen et al in Cancer Cell. Mount...
Is There a Link Between Use of Antibiotics and Early-Onset Colorectal Cancer?
Study findings presented by Perrott et al at the ESMO World Congress on Gastrointestinal Cancer (Abstract SO-25) showed that the use of antibiotics may be linked to colon tumor formation across all patient age groups, especially in those younger than 50 years. These results raise fresh concerns...
BCMA-Directed CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
In the phase Ib/II CARTITUDE-1 trial reported in The Lancet, Jesus G. Berdeja, MD, and colleagues found that ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy with two B-cell maturation antigen (BCMA)-targeting single-domain antibodies, produced a high rate of...
Annual Report to the Nation: Continued Decline in Cancer Death Rate
Overall cancer death rates continue to decline in men and women for all racial and ethnic groups in the United States, according to the latest Annual Report to the Nation on the Status of Cancer. During 2001 to 2018, declines in lung cancer death rates accelerated, and death rates for melanoma...
Is Chemotherapy Associated With Complications or Poorer Outcomes Among Women Undergoing Immediate Breast Reconstruction?
In a cohort study reported in JAMA Surgery, Hart et al found that treatment with either neoadjuvant or adjuvant chemotherapy was not associated with an increased risk of complications or poorer patient-reported outcomes in women undergoing mastectomy for breast cancer with immediate breast...
Parenthood Status and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors
In a Danish population-based study reported in the Journal of Clinical Oncology, Øvlisen et al found that parenthood rates in younger Hodgkin lymphoma survivors who did not experience early relapse were similar to those in the general population, but that use of assisted reproductive techniques...
Using ctDNA to Measure Molecular Residual Disease in Patients With Colorectal Cancer
A team of investigators in Japan used a personalized assay for circulating tumor DNA (ctDNA) levels in plasma to monitor molecular residual disease following surgery in patients with resectable colorectal cancer. Their subgroup analysis found statistically significant associations between ctDNA...
Molecular Imaging May Improve the Staging and Treatment of Pancreatic Ductal Adenocarcinoma
For patients with pancreatic ductal adenocarcinoma, molecular imaging may improve staging and clinical management of the disease, according to research published by Röhrich et al in The Journal of Nuclear Medicine. In a retrospective study of patients with pancreatic ductal adenocarcinomas, the...
Study Recommends Improvements for Cancer Care at Network Sites
New research published in JNCCN—Journal of the National Comprehensive Cancer Network assessed the quality of cancer care delivered through extended sites coordinated by some of the country’s largest cancer centers. The study was developed to implement strategies for disseminating discoveries and...
Donafenib May Improve Survival vs Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma
In a Chinese phase II/III trial reported in the Journal of Clinical Oncology, Qin et al found that donafenib, a multikinase inhibitor and deuterated sorafenib derivative, improved overall survival vs sorafenib in the first-line treatment of unresectable or metastatic hepatocellular carcinoma. As...
Arsenic Plus All-Trans Retinoic Acid for Pediatric Patients With Acute Promyelocytic Leukemia
In a Chinese study (CCLG-APL2016) reported in the Journal of Clinical Oncology, Zheng et al found that the combination of arsenic with all-trans retinoic acid (ATRA) was associated with good survival outcomes in pediatric patients with acute promyelocytic leukemia. Study Details The multicenter...
Mechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients With Cancer
In a study reported in The New England Journal of Medicine, Awad et al identified potential mechanisms of acquired resistance to the KRAS G12C inhibitor adagrasib in patients receiving the agent for treatment of KRAS G12C–mutant cancers. As noted by the investigators, clinical trials of the KRAS...
New Recommendations From WHO and HRP for the Screening and Treatment of Cervical Cancer
The World Health Organization (WHO) and the Human Reproduction Programme (HRP)—the main instrument within the United Nations system for research in human reproduction—have launched a new guideline to help countries make faster progress, more equitably, in the screening and treatment of cervical...
Study Finds Reduced Treatment Delays for Patients With Breast Cancer May Improve Survival Rates
Research published by Pratt et al in Annals of Surgical Oncology showed an increase in survival rates when treatment options—surgery, chemotherapy, and radiation—are completed within 38 weeks from the time of diagnosis for patients with breast cancer. Optimal Treatment Duration The observational...
Individualized Nutritional Support for Patients With Cancer
Among 506 hospitalized patients with cancer at risk of malnutrition, individualized nutritional support reduced the risk of mortality compared to consumption of standard hospital food. The findings from a preplanned secondary analysis of the prospective, randomized, multicenter EFFORT trial,...
Addition of Pembrolizumab to Chemoradiotherapy in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
As reported in JAMA Oncology by Osama E. Rahma, MD, and colleagues, initial results of the phase II NRG-GI002 trial showed no improvement in mean neoadjuvant rectal score with the addition of pembrolizumab to chemoradiotherapy in total neoadjuvant therapy for patients with locally advanced rectal...
Oncolytic Adenovirus for Malignant Glioma: Feasibility and Safety
In a first-in-human phase I trial reported in The Lancet Oncology, Fares et al found that neural stem cell delivery of an oncolytic adenovirus (NSC-CRAd-S-pk7) was safe and feasible in patients with newly diagnosed malignant glioma, with immunologic and histopathologic findings supporting continued ...
International Esodata Study Group Model for Predicting 90-Day Mortality After Esophagectomy
In a retrospective analysis reported by researchers from the International Esodata Study Group (IESG) in JAMA Surgery, D’Journo et al developed a model for predicting risk of 90-day mortality following esophagectomy for patients with esophageal or gastroesophageal junction cancer. As stated by the...
FDA Approves Expanded Indication for Pembrolizumab in Locally Advanced Cutaneous Squamous Cell Carcinoma
On July 6, the U.S. Food and Drug Administration (FDA) approved an expanded label for pembrolizumab, an anti–PD-1 agent, as monotherapy for patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation. This approval is based on data from the second...
Study Explores Co-occurring Mutations in HER2 and HER3
Mutations in a gene related to HER2, a gene frequently implicated in breast cancers and a variety of other malignancies, can amplify activity that spurs tumor growth, according to a new study. The findings, published by Hanker et al in Cancer Cell, could explain why many patients with HER2...
Study Suggests Substantial Delays in Diagnosis and Treatment for Cancer During the COVID-19 Pandemic
A new study has found evidence of the adverse effects the COVID-19 pandemic had on cancer detection and surgical treatments. The study, published by Robin Yabroff, PhD, MBA, and colleagues in JNCI: The Journal of the National Cancer Institute, found a 10.2% decline in real-time electronic pathology ...
Predicting Chemotherapy Resistance in Patients With Gestational Trophoblastic Neoplasia
In a retrospective cohort study reported in The Lancet Oncology, Braga et al identified metastatic disease, choriocarcinoma histology, and higher pretreatment human chorionic gonadotropin concentration as independent predictors of resistance to single-agent chemotherapy in women with low-risk...
Recovery of Gonadal Function With PET-Adapted Regimen for Advanced Hodgkin Lymphoma
In a prospective analysis from the phase III Lymphoma Study Association AHL2011 trial reported in the Journal of Clinical Oncology, Demeestere et al found that patients with advanced Hodgkin lymphoma receiving a positron-emission tomography (PET)-adapted regimen had a reduced risk of gonadal...
Humanized CD19-Targeted CAR T-Cell Treatment in Patients With Relapsed or Refractory B-Cell ALL
In a pilot study reported by Myers et al in the Journal of Clinical Oncology, a humanized CD19-targeted chimeric antigen receptor (CAR) T-cell product developed by the investigators (huCART19) was found to produce durable remissions and prolonged CAR T-cell persistence in CAR-naive and CAR-exposed...
A Shift in the Treatment of Advanced Melanoma
Answers to questions about first-line treatment of metastatic melanoma are “going to be shifting,” Jason J. Luke, MD, told The ASCO Post, with the change coming on the heels of the phase III RELATIVITY-047 trial reported at the 2021 ASCO Annual Meeting.1 That abstract reported that using two...
Responses to Pembrolizumab and Ipilimumab After Anti–PD-1/L1 Failure in Advanced Melanoma
Despite new and effective treatments for melanoma with checkpoint inhibitors and targeted therapies, patients with metastatic melanoma who progress on frontline treatment generally do very poorly. “We really need to make sure we give these patients access to drugs that we know have some efficacy,”...
Efficiency of Virtual Care for Oncology Patients During the COVID-19 Pandemic
In a single-institution study reported in JCO Oncology Practice, Hsiehchen et al found that replacement of in-person with telehealth visits among patients with cancer initiating systemic therapy during the COVID-19 pandemic was not associated with poorer efficiency in components of oncology care or ...
Effect of ALK Amplification and Mutation on Outcomes in High-Risk Neuroblastoma
In an analysis from the European Neuroblastoma Study Group (SIOPEN) HR-NBL1 high-risk neuroblastoma trial reported in the Journal of Clinical Oncology, Bellini et al found that ALK amplification and clonal mutation were associated with poorer outcomes in pediatric patients with high-risk...
Assessment of Targeted Methylation-Based Multicancer Early Detection Test in Independent Validation Cohort
In a validation study reported in Annals of Oncology, Klein et al found that a targeted methylation-based multicancer early detection (MCED) assay using cell-free DNA (cfDNA) sequencing had high specificity for cancer signal detection and high accuracy in predicting cancer signal origin across a...
Second-Line Pembrolizumab Plus Chemotherapy Regimen for Relapsed or Refractory Classic Hodgkin Lymphoma
In a phase II trial reported in the Journal of Clinical Oncology, Alison J. Moskowitz, MD, and colleagues found that second-line therapy with pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in relapsed or refractory classic Hodgkin lymphoma produced responses in all...
FDA Pipeline: Recent Designations in NSCLC, Leukemia, and Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) issued regulatory decisions related to treatments for non–small cell lung cancer (NSCLC), acute leukemia, and mantle cell lymphoma. Breakthrough Therapy Designation for Adagrasib in Advanced NSCLC With KRAS G12C Mutation On June 24, 2021, the...
Phase III Trial Compares Induction Regimens in High-Risk Neuroblastoma
As reported in the Journal of Clinical Oncology by Garaventa et al, the phase III International Society of Pediatric Oncology European Neuroblastoma Group (SIOPEN) HR-NBL1.5 trial showed no significant differences in metastatic complete response rate or event-free survival with the Memorial Sloan...
Effect of Myeloid Progenitor Cell Product on the Risk of Infection During Induction Chemotherapy for AML
In a phase II trial reported in the Journal of Clinical Oncology, Desai et al found that the addition of the myeloid progenitor cell product romyelocel-L to granulocyte colony-stimulating factor (G-CSF) reduced the incidence of infection and antimicrobial use vs G-CSF alone during induction...
Despite Gains in Breast Cancer Survival, Black Women Continue to Experience Significant Mortality Disparities
Although breast cancer continues to be the most common cancer diagnosed in women in the United States, and remains the second-leading cause of cancer death, over the past several decades, the disease has affected Black and White women differently. According to the findings of a large retrospective...
Mortgage Lending Bias and Survival Among Older Women With Breast Cancer in the United States
In a study reported in the Journal of Clinical Oncology, Beyer et al found that redlining (mortgage lending bias on the basis of property location) was associated with overall survival among older U.S. women with breast cancer, with an increasing redlining index (higher likelihood of mortgage loan...
FDA Approves Alternative to E coli–Derived Asparaginase for Leukemia and Lymphoma
On June 30, 2021, the U.S. Food and Drug Administration (FDA) approved asparaginase Erwinia chrysanthemi (recombinant)-rywn (Rylaze) as a component of a multiagent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in adult and pediatric...
Expert Point of View: Rebecca A. Snyder, MD, MPH
The invited discussant of the Alliance A21501 findings, Rebecca A. Snyder, MD, MPH, Assistant Professor of Surgical Oncology at the Brody School of Medicine at East Carolina University, Greenville, described the overall survival associated with modified FOLFIRINOX (fluorouracil [5-FU], leucovorin, ...
Modified FOLFIRINOX Established as Preferred Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer
In the treatment of borderline resectable pancreatic ductal adenocarcinoma, the Alliance A021501 trial established neoadjuvant treatment with modified FOLFIRINOX (fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) as a new benchmark. However, it failed to show the benefit of adding...
Personalizing Treatment of Early HER2-Positive Breast Cancer
With several pivotal trials providing evidence for the escalation and de-escalation of anti-HER2 therapy in certain early breast cancer scenarios, personalized treatment is possible. How can clinicians optimize treatment by applying the studies’ findings? Debu Tripathy, MD, Professor and Chair of...
Association Between Increased BMI and Endometrial Cancer Risk in Asian Women With Postmenopausal Bleeding
The link between obesity and the risk of endometrial cancer has been well documented. A recent study, however, showed that an even lower body mass index (BMI) than previously thought may be associated with an increased risk in Asian women with postmenopausal bleeding. The findings by Liu et al were ...
Study Examines Impact of COVID-19 on Breast and Cervical Cancer Screening Programs
The total number of cancer screening tests received by women through the Centers for Disease Control and Prevention’s (CDC) National Breast and Cervical Cancer Early Detection Program (Early Detection Program) declined by 87% for breast cancer and 84% for cervical cancer during April 2020 as...
Outcomes With 5 vs 2 Years of Zoledronate Treatment Following Adjuvant Chemotherapy in Early Breast Cancer
In the German phase III SUCCESS A trial reported in JAMA Oncology, Friedl et al found no differences in disease-free or overall survival with 5 vs 2 years of zoledronate treatment following adjuvant chemotherapy for early breast cancer. Study Details In the multicenter, open-label, 2 × 2 factorial...
Survey Finds COVID-19 Vaccine Hesitancy Among Many Adolescent and Young Adult Cancer Survivors
Despite recommendations from ASCO and other national organizations that cancer survivors, as well as patients on active treatment, receive the COVID-19 vaccine if they have no contraindications, a survey of adolescent and young adult cancer survivors finds many have vaccine hesitancy. According to...
